Mayne Pharma announces sale of U.S. Generics Portfolio to Dr. Reddy’s
Mayne Pharma’s CEO Mr. Shawn Patrick O’Brien said: “Divesting the retail generics portfolio is an important step forward for the Company as we continue to rationalise our portfolio. With this transaction, we free up working capital, allowing us to more exclusively focus resources on core areas of value for business growth, namely our branded verticals in US women's health and dermatology."
Learn more
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Mayne Pharma Group Limited a question about this update.